drugset
drugset / Trial / NCT00869713

Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

NCT00869713 ↗

Phase 2 Completed 98 enrolled U.S. Army Medical Research and Development Command
NaSingle-groupOpen-labelPrevention

Summary

This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults

Timeline

Start
2009-09
Primary completion
2019-02
Completion
2021-05

Drugs

EvaluationDrugModalityDoseRoute
Subject TSI-GSD 200 Vaccine 1 ml —

Indications

Rift valley fever